本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，北京中关村科技发展（控股）股份有限公司（以下简称：公司）通过 中国证券登记结算有限责任公司查询，获悉： 公司控股股东国美控股集团有限公司（以下简称：国美控股）现持有公司 186,113,207 股，持股比例为 24.71%；国美控股所持有公司的部分股份被法院延 长司法再冻结期限。 国美电器有限公司（以下简称：国美电器）作为国美控股的一致行动人，现 持有公司 50,000,000 股，持股比例为 6.64%；国美电器所持有公司的部分股份被 法院延长司法再冻结期限，部分股份司法再冻结到期，前期被轮候冻结的股份生 效，具体情况如下： 1 股东名称 是否为控 股股东或 第一大股 东及其一 致行动人 司法再冻 结数量 （股） 占其所 持股份 比例 占公司 总股本 比例 司法再冻结 起始日 原司法再冻 结到期日 司法再冻结 到期日（延 期后） 司法再冻结执 行人 国美控股集 团有限公司 是 400,000 0.21% 0.05% 2022-10-10 2025-10-09 2028-09-25 北京市第三中 级人民法院 ...

北京中关村科技发展（控股）股份有限公司（以下简称：公司）下属公司 多多药业有限公司（以下简称：多多药业）于近日收到国家药品监督管理局（以 下简称：国家药监局）签发的《受理通知书》，西格列汀二甲双胍片（II）（规 格：每片含磷酸西格列汀 50mg（以西格列汀计）和盐酸二甲双胍 850mg）上市 许可申请获得受理，现将相关情况公告如下： 一、基本信息 关于下属公司多多药业西格列汀二甲双胍片（II）收到国家药品监督管理局《受理通知书》的公告 共 2 页 证券代码：000931 证券简称：中关村 公告编号：2025-111 北京中关村科技发展（控股）股份有限公司 关于下属公司多多药业西格列汀二甲双胍片（II）收到 国家药品监督管理局《受理通知书》的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 药品名称：西格列汀二甲双胍片（II） 剂型：片剂 规格：每片含磷酸西格列汀 50mg（以西格列汀计）和盐酸二甲双胍 850mg 申请事项：境内生产药品注册上市许可 注册分类：化学药品 4 类 申请人：多多药业有限公司 受理号：CYHS2503626 结论：经审查，决定予以 ...

Core Viewpoint - The company Zhongguancun (000931.SZ) announced that its subsidiary, Duoduo Pharmaceutical Co., Ltd., has received an acceptance notice from the National Medical Products Administration for the marketing authorization application of Sitagliptin Metformin Tablets (II) [1] Group 1 - Duoduo Pharmaceutical's Sitagliptin Metformin Tablets (II) contain 50mg of Sitagliptin (as Sitagliptin phosphate) and 850mg of Metformin hydrochloride per tablet [1] - The product was initiated for development in 2023 and is indicated for use in combination with diet and exercise to treat type 2 diabetes patients whose blood sugar is not adequately controlled on Metformin monotherapy or who are currently receiving dual therapy [1]

Core Viewpoint - Zhongguancun (000931.SZ) announced that its subsidiary, Duoduo Pharmaceutical Co., Ltd., has received an acceptance notice from the National Medical Products Administration for the marketing authorization application of Sitagliptin Metformin Tablets (II) [1] Group 1 - Duoduo Pharmaceutical's Sitagliptin Metformin Tablets (II) contain 50mg of Sitagliptin (as Sitagliptin phosphate) and 850mg of Metformin hydrochloride per tablet [1] - The product was initiated for development in 2023 and is indicated for use in combination with diet and exercise to treat type 2 diabetes patients whose blood sugar remains poorly controlled on Metformin monotherapy or who are currently receiving both treatments [1]

多多药业西格列汀二甲双胍片(II)(规格：每片含磷酸西格列汀50mg(以西格列汀计)和盐酸二甲双胍 850mg)于2023年立项开发，其适应症为：本品配合饮食和运动治疗，用于经二甲双胍单药治疗血糖仍 控制不佳或正在接受二者联合治疗的2型糖尿病患者。 智通财经APP讯，中关村(000931.SZ)发布公告，公司下属公司多多药业有限公司(以下简称：多多药业) 于近日收到国家药品监督管理局(以下简称：国家药监局)签发的《受理通知书》，西格列汀二甲双胍片 (II)(规格：每片含磷酸西格列汀50mg(以西格列汀计)和盐酸二甲双胍850mg)上市许可申请获得受理。 ...

Core Viewpoint - The company Zhongguancun (000931) has received acceptance for the marketing authorization application of its drug, Sitagliptin Metformin Tablets, from the National Medical Products Administration, indicating a significant step in expanding its product portfolio in the diabetes treatment market [1] Company Summary - Zhongguancun's subsidiary, Duoduo Pharmaceutical Co., Ltd., has recently received the acceptance notice for the marketing authorization application of Sitagliptin Metformin Tablets [1] - The drug is indicated for the treatment of type 2 diabetes patients who have inadequate blood sugar control with metformin monotherapy or are currently receiving a combination of both treatments [1] Industry Summary - The acceptance of the drug application highlights the ongoing demand and market potential for diabetes medications, particularly for combination therapies that enhance blood sugar control [1] - The drug contains 50mg of Sitagliptin and 850mg of Metformin per tablet, which aligns with current treatment protocols for managing type 2 diabetes [1]

Core Viewpoint - The announcement indicates that Duoduo Pharmaceutical, a subsidiary of Zhongguancun, has received an acceptance notice from the National Medical Products Administration for the marketing authorization application of Sitagliptin Metformin Tablets (II) [1] Group 1: Product Details - The drug is formulated to contain 50mg of Sitagliptin (as Sitagliptin phosphate) and 850mg of Metformin hydrochloride per tablet [1] - It is indicated for type 2 diabetes patients whose blood sugar is not adequately controlled by Metformin monotherapy or who are currently receiving a combination of both medications [1] Group 2: Financial Implications - As of the date of the announcement, the total research and development expenses for this project have reached 6.8755 million yuan [1] - If the drug is successfully approved, it is expected to enhance the market competitiveness of the company's antidiabetic products and positively impact the company's operating performance [1]

Core Insights - The 2025 World Agricultural Technology Innovation Conference opened in Pinggu, Beijing, with nearly 800 guests from over 90 countries and regions discussing agricultural technology development trends and global food security [1] - New agricultural technology achievements were announced, including the Shennong AI Model 3.0 and Agricultural Zhongguancun 2.0 [1] - According to data from the Food and Agriculture Organization of the United Nations, it is projected that by 2030, 582 million people will still face long-term food shortages globally [1] - Participants engaged in discussions on building resilient food supply systems and the role of AI in future agriculture to collectively address global agricultural challenges [1]

Core Viewpoint - The 2025 Zhongguancun Youth Choir Competition aims to showcase the talents of young individuals in the Zhongguancun Science City through music, fostering a sense of community and cultural exchange [1][2] Group 1: Event Overview - The event took place on October 8 at the Haidian District Cultural Center, featuring performances from various university and youth choir teams [1] - The performances included a mix of classic songs and original works, highlighting the artistic talents of the participants [1] Group 2: Performances - Notable performances included the Beiqing Fans Choir's opening with "I Like" and "Once Upon a Time," and the Central University for Nationalities Choir's rendition of the Yi folk song "Don't Be Afraid" and the inspirational song "Youth" [1] - The Yidou Youth Ethnic Choir presented "Send the Lover" and the original piece "Please Applaud for Me," showcasing the integration of ethnic music with modern choral styles [1] - The Beijing Dolphin Choir performed "There Are So Many People in This World" and "Voice Slow," while the Renmin University Student Art Troupe Choir concluded the event with "Youth Commemorative Album" and "Flowers Blooming Without Worries," reflecting the vibrant spirit and artistic skills of contemporary youth [1] Group 3: Cultural Impact - The event reflects Haidian District's rich cultural atmosphere and youthful vitality, with plans to continue promoting cultural, technological, and economic integration through high-quality cultural activities [2] - The event was organized by the Haidian District Cultural and Tourism Bureau and hosted by the Sanshan Wuyuan Cultural and Art Center [2]

Core Viewpoint - Zhongguancun Science and Technology Leasing (01601) announced the resignation of Mr. Zhang Jian as Chairman of the Board effective August 12, 2025, and the election of Mr. Xu Jingquan as the new Chairman effective September 30, 2025 [1] Group 1 - Mr. Zhang Jian will resign from multiple positions including Chairman, Non-Executive Director, Chairman of the Nomination Committee, member of the Remuneration Committee, member of the Risk Control Committee, and Chairman of the Environmental, Social and Governance Committee, all effective September 30, 2025 [1] - The Board has considered the Nomination Committee's recommendations and proposed the appointment of Mr. Xu Zhengwen as a Non-Executive Director, who will also serve as a member of the Audit Committee upon the effectiveness of his directorship [1]